CEL SCI CORP
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
CVM | NYSE
Overview
Corporate Details
- ISIN(s):
- US1508377066
- LEI:
- Country:
- United States of America
- Address:
- 8229 BOONE BLVD ., 22182 VIENNA
- Website:
- https://cel-sci.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CEL-SCI Corporation is a clinical-stage biotechnology company specializing in the research and development of immunotherapy products for the treatment of cancer, autoimmune diseases, and infectious diseases. The company's lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a pre-surgical treatment for advanced primary head and neck cancer. Its core therapeutic strategy is to activate the patient's immune system before standard treatments like surgery, chemotherapy, or radiation weaken it. A pivotal Phase III study showed Multikine provided a significant 5-year survival benefit. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) platform for autoimmune and infectious diseases, including a potential treatment for Rheumatoid Arthritis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CEL SCI CORP filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CEL SCI CORP
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CEL SCI CORP via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
